Renal Anemia Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Renal Anemia Market Overview – 8 Major Markets 
    3.1    Renal Anemia Market Historical Value (2017-2023) 
    3.2    Renal Anemia Market Forecast Value (2024-2032) 
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Renal Anemia Overview 
    5.1    Guidelines and Stages
    5.2    Pathophysiology
    5.3    Screening and Diagnosis
    5.4    Treatment Pathway 
6    Patient Profile
    6.1    Patient Profile Overview
    6.2    Patient Psychology and Emotional Impact Factors
    6.3    Risk Assessment and Treatment Success Rate
7    Renal Anemia Market - Epidemiology Scenario and Forecast – 8 Major Markets
    7.1    8MM Epidemiology Scenario Overview (2017-2032)
        7.1.1    Prevalence, by Country
            7.1.1.1    United States 
            7.1.1.2    United Kingdom
            7.1.1.3    EU4
            7.1.1.4    India
            7.1.1.5    Japan
        7.1.2    Diagnosed Cases, by Country
            7.1.2.1    United States 
            7.1.2.2    United Kingdom
            7.1.2.3    EU4
            7.1.2.4    India
            7.1.2.5    Japan
        7.1.3    Treatment Seeking Rate, by Country 
            7.1.3.1    United States 
            7.1.3.2    United Kingdom
            7.1.3.3    EU4
            7.1.3.4    India
            7.1.3.5    Japan
8    Renal Anemia Market Landscape – 8 Major Markets 
    8.1    Renal Anemia Market: Developers Landscape
        8.1.1    Analysis by Year of Establishment
        8.1.2    Analysis by Company Size
        8.1.3    Analysis by Region
    8.2    Renal Anemia Market: Product Landscape
        8.2.1    Analysis by Type
        8.2.2    Analysis by Treatment Type
        8.2.3    Analysis by Route of Administration
9    Renal Anemia Market Challenges and Unmet Needs
    9.1    Treatment Pathway Challenges
    9.2    Compliance and Drop-Out Analysis
    9.3    Awareness and Prevention Gaps
10    Cost of Treatment
11    Renal Anemia Market Dynamics
    11.1    Market Drivers and Constraints
    11.2    SWOT Analysis
        11.2.1    Strengths
        11.2.2    Weaknesses
        11.2.3    Opportunities
        11.2.4    Threats
    11.3    PESTEL Analysis
        11.3.1    Political
        11.3.2    Economic
        11.3.3    Social
        11.3.4    Technological
        11.3.5    Legal
        11.3.6    Environment
    11.4    Porter’s Five Forces Model
        11.4.1    Bargaining Power of Suppliers
        11.4.2    Bargaining Power of Buyers
        11.4.3    Threat of New Entrants
        11.4.4    Threat of Substitutes
        11.4.5    Degree of Rivalry
    11.5    Key Demand Indicators 
    11.6    Key Price Indicators
    11.7    Industry Events, Initiatives, and Trends  
    11.8    Value Chain Analysis
12    Renal Anemia Market Segmentation (2017-2032) - 8 Major Markets 
    12.1    Renal Anemia Market (2017-2032) by Type
        12.1.1    Market Overview
        12.1.2    Iron Deficiency Anemia
        12.1.3    Vitamin B12 Deficiency Anemia
        12.1.4    Folate Deficiency Anemia
        12.1.5    Aplastic Anemia
        12.1.6    Sickle Cell Anemia
        12.1.7    Others
    12.2    Renal Anemia Market (2017-2032) by Treatment Type
        12.2.1    Market Overview
        12.2.2    Iron Supplements
        12.2.3    Erythropoiesis-stimulating Agents (ESAs)
        12.2.4    Vitamin B12 Supplements
        12.2.5    Transfusion Therapy
        12.2.6    Bone Marrow Transplant
        12.2.7    Others
    12.3    Renal Anemia Market (2017-2032) by Route of Administration
        12.3.1    Market Overview
        12.3.2    Oral
        12.3.3    Parenteral
        12.3.4    Others
    12.4    Renal Anemia Market (2017-2032) by End-user
        12.4.1    Market Overview
        12.4.2    Hospitals & Clinics
        12.4.3    Homecare Settings
        12.4.4    Dialysis Centers
        12.4.5    Others
    12.5    Renal Anemia Market (2017-2032) by Region
        12.5.1    Market Overview
        12.5.2    United States
        12.5.3    EU-4 and the United Kingdom
            12.5.3.1    Germany
            12.5.3.2    France
            12.5.3.3    Italy
            12.5.3.4    Spain
            12.5.3.5    United Kingdom
        12.5.4    Japan
        12.5.5    India 
13    United States Renal Anemia Market (2017-2032)
    13.1    United States Renal Anemia Market Historical Value (2017-2023) 
    13.2    United States Renal Anemia Market Forecast Value (2024-2032)
    13.3    United States Renal Anemia Market (2017-2032) by Type
        13.3.1    Market Overview
        13.3.2    Iron Deficiency Anemia
        13.3.3    Vitamin B12 Deficiency Anemia
        13.3.4    Folate Deficiency Anemia
        13.3.5    Aplastic Anemia
        13.3.6    Sickle Cell Anemia
        13.3.7    Others
    13.4    United States Renal Anemia Market (2017-2032) by Treatment Type
        13.4.1    Market Overview
        13.4.2    Iron Supplements
        13.4.3    Erythropoiesis-stimulating Agents (ESAs)
        13.4.4    Vitamin B12 Supplements
        13.4.5    Transfusion Therapy
        13.4.6    Bone Marrow Transplant
        13.4.7    Others
    13.5    United States Renal Anemia Market (2017-2032) by Route of Administration
        13.5.1    Market Overview
        13.5.2    Oral
        13.5.3    Parenteral
        13.5.4    Others
    13.6    United States Renal Anemia Market (2017-2032) by End-user
        13.6.1    Market Overview
        13.6.2    Hospitals & Clinics
        13.6.3    Homecare Settings
        13.6.4    Dialysis Centers
        13.6.5    Others
14    EU-4 and United Kingdom Renal Anemia Market (2017-2032)
    14.1    EU-4 and United Kingdom Renal Anemia Market Historical Value (2017-2023) 
    14.2    EU-4 and United Kingdom Renal Anemia Market Forecast Value (2024-2032)
    14.3    EU-4 and United Kingdom Renal Anemia Market (2017-2032) by Type
        14.3.1    Market Overview
        14.3.2    Iron Deficiency Anemia
        14.3.3    Vitamin B12 Deficiency Anemia
        14.3.4    Folate Deficiency Anemia
        14.3.5    Aplastic Anemia
        14.3.6    Sickle Cell Anemia
        14.3.7    Others
    14.4    EU-4 and United Kingdom Renal Anemia Market (2017-2032) by Treatment Type
        14.4.1    Market Overview
        14.4.2    Iron Supplements
        14.4.3    Erythropoiesis-stimulating Agents (ESAs)
        14.4.4    Vitamin B12 Supplements
        14.4.5    Transfusion Therapy
        14.4.6    Bone Marrow Transplant
        14.4.7    Others
    14.5    EU-4 and United Kingdom Renal Anemia Market (2017-2032) by Route of Administration
        14.5.1    Market Overview
        14.5.2    Oral
        14.5.3    Parenteral
        14.5.4    Others
    14.6    EU-4 and United Kingdom Renal Anemia Market (2017-2032) by End-user
        14.6.1    Market Overview
        14.6.2    Hospitals & Clinics
        14.6.3    Homecare Settings
        14.6.4    Dialysis Centers
        14.6.5    Others
15    Japan Renal Anemia Market
    15.1    Japan Renal Anemia Market Historical Value (2017-2023) 
    15.2    Japan Renal Anemia Market Forecast Value (2024-2032)
    15.3    Japan Renal Anemia Market (2017-2032) by Type
        15.3.1    Market Overview
        15.3.2    Iron Deficiency Anemia
        15.3.3    Vitamin B12 Deficiency Anemia
        15.3.4    Folate Deficiency Anemia
        15.3.5    Aplastic Anemia
        15.3.6    Sickle Cell Anemia
        15.3.7    Others
    15.4    Japan Renal Anemia Market (2017-2032) by Treatment Type
        15.4.1    Market Overview
        15.4.2    Iron Supplements
        15.4.3    Erythropoiesis-stimulating Agents (ESAs)
        15.4.4    Vitamin B12 Supplements
        15.4.5    Transfusion Therapy
        15.4.6    Bone Marrow Transplant
        15.4.7    Others
    15.5    Japan Renal Anemia Market (2017-2032) by Route of Administration
        15.5.1    Market Overview
        15.5.2    Oral
        15.5.3    Parenteral
        15.5.4    Others
    15.6    Japan Renal Anemia Market (2017-2032) by End-user
        15.6.1    Market Overview
        15.6.2    Hospitals & Clinics
        15.6.3    Homecare Settings
        15.6.4    Dialysis Centers
        15.6.5    Others
16    India Renal Anemia Market
    16.1    India Renal Anemia Market Historical Value (2017-2023) 
    16.2    India Renal Anemia Market Forecast Value (2024-2032)
    16.3    India Renal Anemia Market (2017-2032) by Type
        16.3.1    Market Overview
        16.3.2    Iron Deficiency Anemia
        16.3.3    Vitamin B12 Deficiency Anemia
        16.3.4    Folate Deficiency Anemia
        16.3.5    Aplastic Anemia
        16.3.6    Sickle Cell Anemia
        16.3.7    Others
    16.4    India Anemia Treatment Market (2017-2032) by Treatment Type
        16.4.1    Market Overview
        16.4.2    Iron Supplements
        16.4.3    Erythropoiesis-stimulating Agents (ESAs)
        16.4.4    Vitamin B12 Supplements
        16.4.5    Transfusion Therapy
        16.4.6    Bone Marrow Transplant
        16.4.7    Others
    16.5    India Renal Anemia Market (2017-2032) by Route of Administration
        16.5.1    Market Overview
        16.5.2    Oral
        16.5.3    Parenteral
        16.5.4    Others
    16.6    India Renal Anemia Market (2017-2032) by End-user
        16.6.1    Market Overview
        16.6.2    Hospitals & Clinics
        16.6.3    Homecare Settings
        16.6.4    Dialysis Centers
        16.6.5    Others
17    Regulatory Framework
    17.1    Regulatory Overview
    17.2    US FDA
    17.3    EU EMA
    17.4    Japan PMDA
    17.5    India CDSCO
    17.6    Others
18    Patent Analysis
    18.1    Analysis by Cancer Type of Patent
    18.2    Analysis by Publication Year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation
19    Clinical Trials Analysis
    19.1    Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Grants Analysis
    20.1    Analysis by Year
    20.2    Analysis by Amount Awarded
    20.3    Analysis by Issuing Authority
    20.4    Analysis by Grant Application
    20.5    Analysis by Funding Institute
    20.6    Analysis by NIH Departments
    20.7    Analysis by Recipient Organization 
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Treatment Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Strategic Initiatives
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Treatment Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Market Share Analysis, By Region (Top 5 Companies)
    23.2    AstraZeneca 
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Company News & Development
        23.2.5    Certifications 
    23.3    GSK plc 
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Company News & Development
        23.3.5    Certifications
    23.4    F. Hoffmann-La Roche Ltd 
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Company News & Development
        23.4.5    Certifications
    23.5    Astellas Pharma 
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Company News & Development
        23.5.5    Certifications
    23.6    Amgen Inc. 
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Company News & Development
        23.6.5    Certifications
    23.7    Otsuka Pharmaceutical Co., Ltd. 
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Company News & Development
        23.7.5    Certifications
    23.8    Takeda Pharmaceutical Company Limited 
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Company News & Development
        23.8.5    Certifications
    23.9    Sanofi 
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Company News & Development
        23.9.5    Certifications
    23.10    AbbVie Inc. 
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Company News & Development
        23.10.5    Certifications
    23.11    Pfizer 
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Company News & Development
        23.11.5    Certifications
24    Renal Anemia Drugs - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.